ArticleACS biomaterials science & engineering2019
Chemotherapeutic Drug Delivery and Quantitative Analysis of Proliferation, Apoptosis, and Migration in a Tissue-Engineered Three-Dimensional Microvessel Model of the Tumor Microenvironment.
Article in ACS biomaterials science & engineering, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Vascularised organoids: Recent advances and applications in cancer research.Clinical and translational medicine · 2025Pooled it
- Retinal organoid screening reveals ABT-737 and luminespib as potential agents against a cone- precursor-derived subtype of retinoblastoma.Molecular therapy. Oncology · 2026Article
- Advances in the Research and Development of Breast Cancer Organoids.Oncology research · 2026Review
- Biogenic nanoparticles: pioneering a new era in breast cancer therapeutics-a comprehensive review.Discover nano · 2024Review
- Tissue-Engineered Microvessels: A Review of Current Engineering Strategies and Applications.Advanced healthcare materials · 2024Review
- A tissue-engineered model of the blood-tumor barrier during metastatic breast cancer.Fluids and barriers of the CNS · 2023Article
- The Cancer Moonshot, the role of in vitro models, model accuracy, and the need for validation.Nature nanotechnology · 2023Article
- Engineering the human blood-brain barrier at the capillary scale using a double-templating technique.Advanced functional materials · 2022Article
- Tumor-on-a-chip: Perfusable vascular incorporation brings new approach to tumor metastasis research and drug development.Frontiers in bioengineering and biotechnology · 2022Review
- Reversible blood-brain barrier opening utilizing the membrane active peptide melittin in vitro and in vivo.Biomaterials · 2021Article
- Fast Stereolithography Printing of Large-Scale Biocompatible Hydrogel Models.Advanced healthcare materials · 2021Article
- A Tissue-Engineered 3D Microvessel Model Reveals the Dynamics of Mosaic Vessel Formation in Breast Cancer.Cancer research · 2020Article
- The mechanical responses of advecting cells in confined flow.Biomicrofluidics · 2020Review
- Tissue-engineered blood-brain barrier models via directed differentiation of human induced pluripotent stem cells.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Numerous approaches have been employed to improve the efficacy of drug and gene delivery systems, but their strategic development is hindered by a lack of mechanistic understanding and assessment of drug transport and action. Optimizing the efficiency of a drug delivery system requires a detailed understanding of the pharmacokinetics, transendothelial transport, distribution at the tumor site, and uptake in target cells. Elucidating transport kinetics and rate-limiting steps in animal models can be extremely challenging, while
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.